Changes in Colorectal Carcinoma Genomes under Anti-EGFR Therapy Identified by Whole-Genome Plasma DNA Sequencing

PLoS Genetics

Volumn 10, Issue 3, 2014, Pages

  Mohan, Sumitra ^a   Heitzer, Ellen ^a   Ulz, Peter ^a   Lafer, Ingrid ^a   Lax, Sigurd ^b   Auer, Martina ^a   Pichler, Martin ^a   Gerger, Armin ^a   Eisner, Florian ^a   Hoefler, Gerald ^a   Bauernhofer, Thomas ^a   Geigl, Jochen B ^a   Speicher, Michael R ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b General Hospital Graz West   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; PANITUMUMAB; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MET PROTEIN, HUMAN; MONOCLONAL ANTIBODY; SCATTER FACTOR RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BRAF GENE; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE COURSE; DNA SEQUENCE; DRUG EFFICACY; EGFR GENE; FEMALE; GENE; GENE AMPLIFICATION; GENE DOSAGE; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; KRAS GENE; MALE; METASTASIS; MIDDLE AGED; PIK3CA GENE; TREATMENT DURATION; TREATMENT RESPONSE; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; BLOOD; COLORECTAL NEOPLASMS; DRUG RESISTANCE; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN GENOME; IMMUNOLOGY; MUTATION; PATHOLOGY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENOME, HUMAN; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 84897389811     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1004271     Document Type: Article

References (53)

1. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, et al. (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765.
2. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, et al. (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408-1417.
3. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634.
4. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345.
5. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, et al. (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: 1658-1664.
6. Evaluation of Genomic Applications in Practice and Prevention Working Group (2013) Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy? Genet Med 15: 517-527.
7. Lin JS, Webber EM, Senger CA, Holmes RS, Whitlock EP, (2011) Systematic review of pharmacogenetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancer. Am J Cancer Res 1: 650-662.
8. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, et al. (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11: 753-762.
9. De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S, (2011) KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 12: 594-603.
10. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, et al. (2009) Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27: 5924-5930.
11. Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL, (2009) Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 28: 3801-3813.
12. Lu Y, Li X, Liang K, Luwor R, Siddik ZH, et al. (2007) Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer Res 67: 8240-8247.
13. Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, et al. (2011) Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 3: 99ra86.
14. Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, et al. (2011) A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 1: 508-523.
15. Valtorta E, Misale S, Sartore-Bianchi A, Nagtegaal ID, Paraf F, et al. (2013) KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. Int J Cancer 133: 1259-1265.
16. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, et al. (2012) Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486: 532-536.
17. Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, et al. (2013) Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov 3: 658-673.
18. Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, et al. (2012) Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med 18: 221-223.
19. Cappuzzo F, Finocchiaro G, Rossi E, Janne PA, Carnaghi C, et al. (2008) EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 19: 717-723.
20. Personeni N, Fieuws S, Piessevaux H, De Hertogh G, De Schutter J, et al. (2008) Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clin Cancer Res 14: 5869-5876.
21. Sartore-Bianchi A, Moroni M, Veronese S, Carnaghi C, Bajetta E, et al. (2007) Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 25: 3238-3245.
22. Chan KC, Jiang P, Zheng YW, Liao GJ, Sun H, et al. (2013) Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem 59: 211-224.
23. Diehl F, Li M, Dressman D, He Y, Shen D, et al. (2005) Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A 102: 16368-16373.
24. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, et al. (2008) Circulating mutant DNA to assess tumor dynamics. Nat Med 14: 985-990.
25. Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, et al. (2012) Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 4: 136ra168.
26. Heitzer E, Auer M, Hoffmann EM, Pichler M, Gasch C, et al. (2013) Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. Int J Cancer 133: 346-356.
27. Leary RJ, Kinde I, Diehl F, Schmidt K, Clouser C, et al. (2010) Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med 2: 20ra14.
28. Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, et al. (2012) Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 4: 162ra154.
29. McBride DJ, Orpana AK, Sotiriou C, Joensuu H, Stephens PJ, et al. (2010) Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes Cancer 49: 1062-1069.
30. Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, et al. (2013) Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497: 108-112.
31. Schwarzenbach H, Hoon DS, Pantel K, (2011) Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11: 426-437.
32. Heitzer E, Ulz P, Belic J, Gutschi S, Quehenberger F, et al. (2013) Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med 5: 30.
33. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A, (2013) Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 10: 472-484.
34. Heitzer E, Auer M, Ulz P, Geigl JB, Speicher MR, (2013) Circulating tumor cells and DNA as liquid biopsies. Genome Med 5: 73.
35. Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, et al. (2012) The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486: 537-540.
36. Cai H, Kumar N, Ai N, Gupta S, Rath P, et al. (2013) Progenetix: 12 years of oncogenomic data curation. Nucleic Acids Res 42: D1055-62 doi: 10.1093/nar/gkt1108.
37. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, et al. (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369: 1023-1034.
38. Kidess E, Jeffrey SS, (2013) Circulating tumor cells versus tumor-derived cell-free DNA: rivals or partners in cancer care in the era of single-cell analysis? Genome Med 5: 70.
39. Auer M, Heitzer E, Ulz P, Geigl JB, Speicher MR, (2013) Single circulating tumor cell sequencing for monitoring. Oncotarget 4: 812-813.
40. Smith G, Bounds R, Wolf H, Steele RJ, Carey FA, et al. (2010) Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours- implications for personalised cancer medicine. Br J Cancer 102: 693-703.
41. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, et al. (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26: 5705-5712.
42. Bardelli A, Janne PA, (2012) The road to resistance: EGFR mutation and cetuximab. Nat Med 18: 199-200.
43. Cancer Genome Atlas N (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330-337.
44. Cappuzzo F, Janne PA, Skokan M, Finocchiaro G, Rossi E, et al. (2009) MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol 20: 298-304.
45. Inno A, Di Salvatore M, Cenci T, Martini M, Orlandi A, et al. (2011) Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? Clin Colorectal Cancer 10: 325-332.
46. Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, et al. (2009) PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 27: 2622-2629.
47. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, Molinari F, De Dosso S, et al. (2009) Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 4: e7287.
48. Heitzer E, Auer M, Gasch C, Pichler M, Ulz P, et al. (2013) Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res 73: 2965-2975.
49. Li H, Durbin R, (2009) Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25: 1754-1760.
50. Thorvaldsdottir H, Robinson JT, Mesirov JP, (2013) Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform 14: 178-192.
51. Olshen AB, Venkatraman ES, Lucito R, Wigler M, (2004) Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5: 557-572.
52. Hupe P, Stransky N, Thiery JP, Radvanyi F, Barillot E, (2004) Analysis of array CGH data: from signal ratio to gain and loss of DNA regions. Bioinformatics 20: 3413-3422.
53. Lai W, Choudhary V, Park PJ, (2008) CGHweb: a tool for comparing DNA copy number segmentations from multiple algorithms. Bioinformatics 24: 1014-1015.